Amongst the first to be recognized for this distinguished milestone
Reaffirms Lupin’s commitment to sustainable resource management

Mumbai, December 05, 2024: Global pharma major Lupin Limited (Lupin) today announced that its R&D facility at Lupin Research Park, Pune has been awarded the LEED Platinum Certification for Operations and Maintenance by the U.S. Green Building Council (USGBC), the global leader in green building certifications. The facility was designed to be a LEED Platinum building and inaugurated in 2017 and has retained the highest level of certification after 7 years of operations. This recognition makes Lupin one of the first Indian pharmaceutical companies to achieve this distinguished milestone.

Commenting on this achievement, Nilesh Gupta, Managing Director, Lupin, said, “We are delighted to be awarded the prestigious LEED Platinum Certification for our Research facility at Lupin Research Park, a significant landmark for us as well as the Indian pharma sector. This accomplishment is a testament to our team’s commitment to innovation, sustainability and creating a lasting positive impact on the environment.”

Lupin prioritizes sustainability across its operations, spearheading initiatives that reduce dependency on fossil fuels and enhance resource efficiency. At the Pune R&D facility, these efforts have resulted in significant environmental benefits including:

• Energy Efficiency and Renewable Energy Adoption: The facility utilizes green energy sources through a mix of on-site and off-site initiatives.
• Water Conservation Measures: Advanced water efficiency strategies have reduced the facility’s reliance on external sources, conserving a critical natural resource.
• Sustainable Waste Management: Adhering to the principles of reduce, reuse, recycle and repurpose, the Pune facility achieves near-zero waste to landfill, aligning with LEED’s global sustainability standards.
• Healthy Workspaces: The facility’s design and operational practices ensure superior indoor air quality, creating a healthy and comfortable environment for its occupants.

These comprehensive efforts reflect Lupin’s forward-looking approach to sustainability, showcasing its leadership in embedding environmentally conscious practices efficiently into its operations.

About the U.S. Green Building Council
The U.S. Green Building Council is a non-profit trade organization that promotes sustainability in how buildings are designed, built and operated. The LEED certification program was developed to provide property owners and operators with strategies for improving the performance of buildings through energy savings, water efficiency, indoor environmental quality, stewardship of resources and other measures. By using less energy, LEED-certified buildings save money, reduce greenhouse gas emissions, and contribute to a healthier environment for residents, workers and the larger community. For more information, please visit www.usgbc.org

About Green Building Certification Inc.
Green Building Certification Inc. is a premier organization for independently recognizing excellence in green building industry performance and practice globally, through third-party verification services for certification and credentialing. GBCI was founded in January 2008 with the support of the U.S. Green Building Council (USGBC) to provide independent oversight of professional credentialing and project certification under the Leadership in Energy and Environmental Design (LEED) green building rating system. For more information, please visit https://www.gbci.org/

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries please contact:

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com